Who
Angus C. Russell
Director
Company insider
Files Form 4 as: Director, Lineage Cell Therapeutics; Director, Structure Therapeutics; Director, Revance Therapeutics; Director, TherapeuticsMD; Director, Mallinckrodt; Director, Intermune; Director, Questcor Pharmaceuticals.
In numbers
- Trades disclosed
- 111
- Buys
- 10
- Sells
- 2
- Bought
- $961K
- Sold
- $21K
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 31 Oct 2011
- Last trade
- 1 Jul 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 2 Jul 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,453 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,453 at $0.00 | filing |
| 1 Jul 2025filed 2 Jul 2025 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 23 Jun 2025filed 25 Jun 2025 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,833 at $0.00 | filing |
| 6 Feb 2025filed 6 Feb 2025 | Revance Therapeutics | SEC FORM 4 Code D | —15,000 | filing |
| 4 Feb 2025filed 6 Feb 2025 | Revance Therapeutics | SEC FORM 4 Code U | $133K36,506 at $3.65 | filing |
| 26 Aug 2024filed 28 Aug 2024 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Jul 2024filed 3 Jul 2024 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 May 2024filed 3 May 2024 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —23,458 at $0.00 | filing |
| 1 May 2024filed 3 May 2024 | Revance Therapeutics | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 1 Jul 2023filed 3 Jul 2023 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 3 May 2023filed 5 May 2023 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —5,915 at $0.00 | filing |
| 3 May 2023filed 5 May 2023 | Revance Therapeutics | SEC FORM 4 Code A | —3,534 at $0.00 | filing |
| 29 Sep 2022filed 3 Oct 2022 | TXMD TherapeuticsMDoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 18 Aug 2022filed 22 Aug 2022 | TXMD TherapeuticsMDoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,984 at $0.00 | filing |
| 18 Aug 2022filed 22 Aug 2022 | TXMD TherapeuticsMDBiotechnology | SEC FORM 4 Code M | —1,984 | filing |
| 1 Jul 2022filed 6 Jul 2022 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 4 May 2022filed 13 May 2022 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —10,756 at $0.00 | filing |
News
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 1.2% – What's Next?LCTX · dailypolitical.com · 17 Oct 2026TherapeuticsMD (NASDAQ:TXMD) vs. Addex Therapeutics (NASDAQ:ADXN) Head to Head ComparisonTXMD · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Angus C. Russell; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.